Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.2.1. Product
1.2.2. Technology
1.2.3. Application
1.2.4. End-use
1.3. Information analysis
1.4. Market formulation & data visualization
1.5. Data validation & publishing
1.6. Information Procurement
1.6.1. Primary Research
1.7. Information or Data Analysis
1.8. Market Formulation & Validation
1.9. Market Model
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Increasing prevalence of cancer
3.2.1.2. Rising geriatric patient population
3.2.1.3. Increasing government initiatives
3.2.2. Market Restraint Analysis
3.2.2.1. Lack of standardization in epigenetics-based diagnostics
3.2.2.2. Lack of skilled professionals
3.3. Industry Analysis Tools
3.3.1. Porter's Five Forces Analysis
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis
Chapter 4. U.S. Epigenetics Market: Product Business Analysis
4.1. Segment Dashboard
4.2. U.S. Epigenetics Market Product Movement Analysis
4.3. U.S. Epigenetics Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
4.4. Reagents
4.4.1. Reagents market estimates and forecast, 2018-2030 (USD Million)
4.5. Kits
4.5.1. Kits market estimates and forecast, 2018-2030 (USD Million)
4.5.2. ChIP Sequencing Kit
4.5.2.1. ChIP sequencing kit market estimates and forecast, 2018-2030 (USD Million)
4.5.3. Whole Genomic Amplification Kit
4.5.3.1. Whole genomic amplification kit market estimates and forecast, 2018-2030 (USD Million)
4.5.4. Bisulfite Conversion Kit
4.5.4.1. Bisulfite conversion kit market estimates and forecast, 2018-2030 (USD Million)
4.5.5. RNA Sequencing Kit
4.5.5.1. RNA sequencing kit market estimates and forecast, 2018-2030 (USD Million)
4.5.6. Others
4.5.6.1. Others market estimates and forecast, 2018-2030 (USD Million)
4.6. Instruments
4.6.1. Instruments market estimates and forecast, 2018-2030 (USD Million)
4.7. Enzymes
4.7.1. Enzymes market estimates and forecast, 2018-2030 (USD Million)
4.8. Services
4.8.1. Services market estimates and forecast, 2018-2030 (USD Million)
Chapter 5. U.S. Epigenetics Market: Technology Business Analysis
5.1. Segment Dashboard
5.2. U.S. Epigenetics Market Technology Movement Analysis
5.3. U.S. Epigenetics Synthesis Market Size & Trend Analysis, by Technology, 2018 to 2030 (USD Million)
5.4. DNA Methylation
5.4.1. DNA methylation market estimates and forecast, 2018-2030 (USD Million)
5.5. Histone Methylation
5.5.1. Histone methylation market estimates and forecast, 2018-2030 (USD Million)
5.6. Histone Acetylation
5.6.1. Histone acetylation market estimates and forecast, 2018-2030 (USD Million)
5.7. Large Non - coding RNA
5.7.1. Large non - coding RNA market estimates and forecast, 2018-2030 (USD Million)
5.8. MicroRNA Modification
5.8.1. MicroRNA modification market estimates and forecast, 2018-2030 (USD Million)
5.9. Chromatin Structures
5.9.1. Chromatin structures market estimates and forecast, 2018-2030 (USD Million)
Chapter 6. U.S. Epigenetics Market: Application Business Analysis
6.1. Segment Dashboard
6.2. U.S. Epigenetics Market Application Movement Analysis
6.3. U.S. Epigenetics Synthesis Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
6.4. Oncology
6.4.1. Oncology market estimates and forecast, 2018-2030 (USD Million)
6.4.2. Solid Tumors
6.4.2.1. Solid tumors market estimates and forecast, 2018-2030 (USD Million)
6.4.3. Liquid Tumors
6.4.3.1. Liquid tumors market estimates and forecast, 2018-2030 (USD Million)
6.5. Non-oncology
6.5.1. Non-oncology market estimates and forecast, 2018-2030 (USD Million)
6.5.2. Inflammatory Diseases
6.5.2.1. Inflammatory diseases market estimates and forecast, 2018-2030 (USD Million)
6.5.3. Metabolic Diseases
6.5.3.1. Metabolic diseases market estimates and forecast, 2018-2030 (USD Million)
6.5.4. Infectious Diseases
6.5.4.1. Infectious diseases market estimates and forecast, 2018-2030 (USD Million)
6.5.5. Cardiovascular Diseases
6.5.5.1. Cardiovascular diseases market estimates and forecast, 2018-2030 (USD Million)
6.5.6. Others
6.5.6.1. Others market estimates and forecast, 2018-2030 (USD Million)
Chapter 7. U.S. Epigenetics Market: End-use Business Analysis
7.1. Segment Dashboard
7.2. U.S. Epigenetics Market End-use Movement Analysis
7.3. U.S. Epigenetics Market Size & Trend Analysis, by End-use, 2018 to 2030 (USD Million)
7.4. Academic Research
7.4.1. Academic research market estimates and forecast, 2018-2030 (USD Million)
7.5. Clinical Research
7.5.1. Clinical research market estimates and forecast, 2018-2030 (USD Million)
7.6. Hospitals & Clinics
7.6.1. Hospitals & clinics market estimates and forecast, 2018-2030 (USD Million)
7.7. Pharmaceutical & Biotechnology Companies
7.7.1. Pharmaceutical & biotechnology companies market estimates and forecast, 2018-2030 (USD Million)
7.8. Others
7.8.1. Others market estimates and forecast, 2018-2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Participant Categorization
8.2. Strategy Mapping
8.3. Company Market Position Analysis, 2023
8.4. Participant’s Overview
8.4.1. Roche Diagnostics
8.4.1.1. Overview
8.4.1.2. Financial performance
8.4.1.3. Product & service benchmarking
8.4.1.4. Strategic initiatives
8.4.2. Thermo Fisher Scientific, Inc.
8.4.2.1. Overview
8.4.2.2. Financial performance
8.4.2.3. Product & service benchmarking
8.4.2.4. Strategic initiatives
8.4.3. Danaher
8.4.3.1. Overview
8.4.3.2. Financial performance
8.4.3.3. Product & service benchmarking
8.4.3.4. Strategic initiatives
8.4.4. Eisai Co. Ltd.
8.4.4.1. Overview
8.4.4.2. Financial performance
8.4.4.3. Product & service benchmarking
8.4.4.4. Strategic initiatives
8.4.5. Novartis AG
8.4.5.1. Overview
8.4.5.2. Financial performance
8.4.5.3. Product & service benchmarking
8.4.5.4. Strategic initiatives
8.4.6. Element Biosciences, Inc.
8.4.6.1. Overview
8.4.6.2. Financial performance
8.4.6.3. Product & service benchmarking
8.4.6.4. Strategic initiatives
8.4.7. Dovetail Genomics LLC.
8.4.7.1. Overview
8.4.7.2. Financial performance
8.4.7.3. Product & service benchmarking
8.4.7.4. Strategic initiatives
8.4.8. Illumina, Inc.
8.4.8.1. Overview
8.4.8.2. Financial performance
8.4.8.3. Product & service benchmarking
8.4.8.4. Strategic initiatives
8.4.9. Promega Corporation.
8.4.9.1. Overview
8.4.9.2. Financial performance
8.4.9.3. Product & service benchmarking
8.4.9.4. Strategic initiatives
8.4.10. Abcam plc.
8.4.10.1. Overview
8.4.10.2. Financial performance
8.4.10.3. Product & service benchmarking
8.4.10.4. Strategic initiatives
List of Tables
Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 U.S. epigenetics market, by product, 2018-2030 (USD Million)
Table 4 U.S. epigenetics market, by technology, 2018-2030 (USD Million)
Table 5 U.S. epigenetics market, by application, 2018-2030 (USD Million)
Table 6 U.S. epigenetics market, by end-use, 2018-2030 (USD Million)
Table 7 Participant's overview
Table 8 Financial performance
Table 9 Key companies undergoing expansions
Table 10 Key companies undergoing acquisitions
Table 11 Key companies undergoing collaborations
Table 12 Key companies launching new products/services
Table 13 Key companies undertaking other strategies
List of Figures
Figure 1 U.S. epigenetics market segmentation
Figure 2 Market research process
Figure 3 Data triangulation techniques
Figure 4 Primary research pattern
Figure 5 Market research approaches
Figure 6 Value-chain-based sizing & forecasting
Figure 7 QFD modeling for market share assessment
Figure 8 Market formulation & validation
Figure 9 Market outlook
Figure 10 Segment snapshot
Figure 11 Competitive landscape snapshot
Figure 12 Parent market outlook
Figure 13 U.S. epigenetics market driver analysis
Figure 14 U.S. epigenetics market restraint analysis
Figure 15 U.S. epigenetics market: Porter's analysis
Figure 16 U.S. epigenetics market: Product outlook key takeaways
Figure 17 U.S. epigenetics market: Product movement analysis
Figure 18 Reagents market estimates and forecast, 2018-2030 (USD Million)
Figure 19 Kits market estimates and forecast, 2018-2030 (USD Million)
Figure 20 ChIP sequencing kit market estimates and forecast, 2018-2030 (USD Million)
Figure 21 Whole genomic amplification kit market estimates and forecast, 2018-2030 (USD Million)
Figure 22 Bisulfite conversion kit market estimates and forecast, 2018-2030 (USD Million)
Figure 23 RNA sequencing kit market estimates and forecast, 2018-2030 (USD Million)
Figure 24 Others market estimates and forecast, 2018-2030 (USD Million)
Figure 25 U.S. epigenetics market: Technology movement analysis
Figure 26 U.S. epigenetics market: Technology outlook and key takeaways
Figure 27 DNA methylation market estimates and forecast, 2018-2030 (USD Million)
Figure 28 Histone methylation market estimates and forecast, 2018-2030 (USD Million)
Figure 29 Histone acetylation market estimates and forecast, 2018-2030 (USD Million)
Figure 30 Large non - coding RNA market estimates and forecast, 2018-2030 (USD Million)
Figure 31 MicroRNA modification market estimates and forecast, 2018-2030 (USD Million)
Figure 32 Chromatin structures market estimates and forecast, 2018-2030 (USD Million)
Figure 33 U.S. epigenetics market: Application movement analysis
Figure 34 U.S. epigenetics market: Application outlook and key takeaways
Figure 35 Oncology market estimates and forecast, 2018-2030 (USD Million)
Figure 36 Solid tumors market estimates and forecast, 2018-2030 (USD Million)
Figure 37 Liquid tumors market estimates and forecast, 2018-2030 (USD Million)
Figure 38 Non-oncology market estimates and forecast, 2018-2030 (USD Million)
Figure 39 Inflammatory diseases market estimates and forecast, 2018-2030 (USD Million)
Figure 40 Metabolic diseases market estimates and forecast, 2018-2030 (USD Million)
Figure 41 Infectious diseases market estimates and forecast, 2018-2030 (USD Million)
Figure 42 Cardiovascular diseases market estimates and forecast, 2018-2030 (USD Million)
Figure 43 Others market estimates and forecast, 2018-2030 (USD Million)
Figure 44 U.S. epigenetics market End-use outlook key takeaways
Figure 45 U.S. epigenetics market: End-use movement analysis
Figure 46 Academic research market estimates and forecast, 2018-2030 (USD Million))
Figure 47 Clinical research market estimates and forecast, 2018-2030 (USD Million)
Figure 48 Hospitals & clinics market estimates and forecast, 2018-2030 (USD Million)
Figure 49 Pharmaceutical & biotechnology companies market estimates and forecast, 2018-2030 (USD Million)
Figure 50 Others market estimates and forecast, 2018-2030 (USD Million)
Figure 51 Key company categorization
Figure 52 Company market positioning
Figure 53 Market participant categorization
Figure 54 Strategy framework